Health Discovery Corporation Announces Issuance of New U.S. Patent Covering SVM-Based Image Analysis Including Digital Mammography Business Editors / Health/Medical Writers
SAVANNAH, Ga.--(BUSINESS WIRE)--Feb. 9, 2006-- Health Discovery Corporation ("HDC") (OTCBB:HDVY) announced that this week the U.S. Patent and Trademark Office issued the Company its latest SVM-related patent, Patent No. 6,996,549, covering the use of multiple Support Vector Machines ("SVM") for processing different types of data that can be extracted from digitized images such as those found in digital mammography.
Last fall, the New England Journal of Medicine reported a landmark breast cancer screening trial showing that digital mammography detected more cancers -- up to 28% more -- than screen film mammography in certain groups of women. Millennium Research Group, a medical device analysis firm, has predicted significant growth in the market for digital breast imaging, from about $200M in 2004 to more than $450M by 2009. A key to successful market growth will be implementation of computer-aided detection software, such as that covered by HDC's newest patent. HDC now owns seventeen (17) issued U.S. and foreign patents covering uses of SVM pattern recognition technology.
Most currently available software for digital mammography rely on artificial neural networks. Neural network classification methods, which have been in use for image classification for a decade or more, suffer from a number of drawbacks that negatively impact their reliability. Published research has shown that SVMs are superior to neural networks in characterizing microcalcification clusters in digitized mammograms.
"This latest issuance adds considerable strength to our entire SVM intellectual property portfolio," said Stephen D. Barnhill, M.D., HDC's Chairman & CEO. "We now hold pioneer patents covering a range of SVM applications from pre-processing all the way through to instantaneous diagnosis and monitoring of diseases over the Internet. This presents the opportunity for physicians around the world to gain point 'n' click access to the most advanced computer assisted diagnostic ("CAD") tools for analysis of blood, tissues and all digital images such as X-rays, MRI's, PET scans and others."
Other applications of HDC's newly issued patent include analysis of microscopic images of samples, such as tissue and blood, from a patient. Examples of such applications for blood samples include circulating tumor and endothelial cell analyses, which are gaining recognition as predictive of outcome in certain cancers like breast cancer and have significant value in determining the direction and monitoring efficacy of treatment. Examples of tissue samples include microscopic images for surgical specimens, PAP smears and biopsies for determining diagnosis and progression of cancer. The ability to automatically analyze every image using CAD software and produce a summary result, as provided by HDC's patented method, greatly increases the reliability of the analysis as well as the time required to complete it. HDC's additional claims covering in vivo analysis methods and their applications are pending before the U.S. Patent Office.
HDC's issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple SVMs and for multiple data sets, and providing SVM analysis services over the Internet. HDC's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVM's including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.
IP: Logged |
posted
SAVANNAH, Ga.--(BUSINESS WIRE)--Feb. 14, 2006-- Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced today that it has expanded its present licensing and product development relationship with Clarient, Inc. (NasdaqSC: CLRT). Under the expanded agreement, Clarient will now utilize HDC's Support Vector Machine (SVM) technology for the analysis and interpretation of flow cytometry. The two companies will continue their ongoing collaboration and product development in the areas of circulating tumor cells for breast cancer and circulating endothelial cells for angiogenesis.
Dr. Herbert Fritsche, Professor and Director of Clinical Chemistry at the M.D. Anderson Cancer Center and Chairman of HDC's Scientific Team, commented: "While initially used for biomedical research, flow cytometers are now being used for cancer diagnosis and monitoring, drug discovery, stem cell and gene therapy, and DNA diagnostics. The expanded partnership between Clarient and HDC combines the most advanced laboratory techniques with state-of-the-art SVM pattern recognition tools. This partnership will offer physicians a unique opportunity to better evaluate and monitor patients which is a critical step forward in the advancement of personalized medicine."
Flow cytometry technology impacts both basic cell biology and clinical medicine in a very significant manner as a powerful technique for making measurements on single particles and cells. The technology allows for the evaluation of a large number of cells in a very short period of time: some systems can run at rates approaching 100,000 particles per second while collecting the 10 to 20 variable parameters on each cell.
"Expanding our partnership with Clarient into flow cytometry stands as further endorsement of the power of our pattern recognition technology," said Stephen D. Barnhill, M.D., HDC's Chairman and Chief Executive Officer. "Given the high dimensional complexity of the flow cytometry data, our SVM technology is a perfect analytical tool and will ultimately offer pathologists and physicians a more meaningful analysis and interpretation than presently available. HDC also clearly benefits from Clarient's recognized leadership in cancer diagnostics and its recently expanded clinical laboratory. This state-of-the-art clinical laboratory is an ideal outlet for future commercialization of these newly developed diagnostic products and represents a significant opportunity for near-term and future revenues."
IP: Logged |
posted
Oh yaa ! told you something was up this should bring it up some today !!!! Join the ride its at 0.10 right now cheap to buy in !!!!!
IP: Logged |
posted
IMO this is more for those of you that want a more stable stock. Im pretty sure that it will keep gradually going up as more and more news is released. But do your own DD.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
